| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -12.1 | -14.4 |
| EPS (diluted, $ a share) | $-0.11 | $-0.28 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: QUIT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Achieve Life Sciences, Inc.: key numbers
- Share price
- $6.06Close, Nov 16
- Market cap
- $667M
- Shares outstanding
- 110.03MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Achieve Life Sciences, Inc.
All →Achieve Life Sciences Financial Results
Achieve Life Sciences (rebranded as AchieveRx) reported third quarter 2026 financial results and provided a regulatory update on its smoking cessation drug, cytisinicline. The company remains on track to resubmit its New Drug Application (NDA) to the FDA in Q4 2026 and ended the period with $201.5 million in cash and equivalents.
- Term
- Q3 2026
“Becoming AchieveRx, The Quit Company, reflects our shift from a clinical-stage company to one preparing to launch what could be the first new FDA-approved prescription medicine in 20 years to help people who smoke quit.”
Andrew D. Goldberg, MD, Chief Executive Officer
“Our 52-week ORCA-OL results add to the growing body of evidence supporting cytisinicline as a potential treatment option for people looking to quit smoking. With an experienced launch team and our NDA resubmission on track for later this year, we are well positioned to bring cytisinicline to people who want to quit, if it is approved.”
Andrew D. Goldberg, MD, Chief Executive Officer
Achieve Life Sciences Executive Compensation
Achieve Life Sciences appointed Benjamin Halladay as Chief Financial Officer, effective October 5, 2026. His compensation package includes a $525,000 base salary, a 40% target bonus, and equity awards consisting of 200,000 stock options and 200,000 restricted stock units. The agreement also provides for severance benefits ranging from 9 to 12 months of salary depending on the circumstances of termination.
- Counterparty
- Benjamin Halladay